10-Q: Microbot Medical Reports First Quarter 2024 Results, Advances Robotic Surgery System

Microbot Medical reported its first quarter 2024 financial results, highlighting progress in its robotic surgery system development and ongoing financial challenges.

Summary

• Microbot Medical reported a net loss of $2.37 million for the first quarter of 2024, compared to a net loss of $2.85 million for the same period in 2023.
• The company's research and development expenses decreased to $1.17 million from $1.62 million year-over-year, primarily due to reduced payroll and manufacturing outsourcing costs.
• General and administrative expenses also decreased slightly to $1.22 million from $1.30 million year-over-year.
• The company's cash and cash equivalents, along with marketable securities, totaled approximately $6.35 million as of March 31, 2024.
• Microbot raised approximately $2.7 million in gross proceeds from financing activities in January 2024.
• The company submitted an Investigational Device Exemption (IDE) application to the FDA for its LIBERTY Endovascular Robotic Surgical System and anticipates 510(k) clearance in the first half of 2025.
• Microbot also expects to receive CE Mark approval for the LIBERTY system in the second half of 2025.
• The company is obligated to pay royalties on future sales related to government grants received from the Israeli Innovation Authority and the Ministry of Economy.

Sentiment

Score: 4

Explanation: The document presents a mixed picture. While there is progress in the development of the LIBERTY system and some cost reductions, the company's financial situation is precarious, with ongoing losses and a going concern warning. The dependence on future capital raises and the risks associated with the war in Israel add to the negative sentiment.

Positives

• The company's net loss decreased year-over-year, indicating improved cost management.
• Research and development expenses decreased, suggesting more efficient use of resources.
• The company successfully completed a pivotal preclinical study with its LIBERTY system, demonstrating its potential.
• Microbot submitted an IDE application to the FDA, marking a significant step towards commercialization.
• The company secured additional funding through financing activities in January 2024.
• The company has a clear timeline for FDA 510(k) clearance and CE Mark approval.

Negatives

• The company continues to operate at a loss, with a net loss of $2.37 million in Q1 2024.
• The company has not generated any revenue from operations.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company is dependent on raising additional capital to fund its operations and development activities.
• The company is subject to risks related to the ongoing war in Israel, which could impact its operations and supply chain.
• The company is obligated to pay royalties on future sales related to government grants.

Risks

• The company's ability to continue as a going concern is uncertain due to its ongoing losses and need for additional funding.
• The ongoing war in Israel poses risks to the company's operations, supply chain, and ability to meet milestones.
• The company's success is dependent on obtaining regulatory approvals for its LIBERTY system, which is not guaranteed.
• The company faces competition in the medical device industry, which could impact its market share.
• The company's reliance on government grants and future capital raises exposes it to financial risks.
• The company is subject to risks related to foreign exchange fluctuations.

Future Outlook

Microbot anticipates receiving 510(k) clearance from the FDA in the first half of 2025 and CE Mark approval in the second half of 2025. The company will continue to seek additional funding through public and private issuances of debt and/or equity securities.

Management Comments

• Management believes they have sufficient funds for operations for less than one year.
• Management is closely monitoring the ongoing war in Israel and its potential impact on the company's operations.
• Management is unable to predict the likelihood of securing additional capital.

Industry Context

Microbot Medical is operating in the competitive medical device industry, specifically in the robotic surgery space. The company's focus on developing a fully disposable robotic system for endovascular procedures is a unique approach that could differentiate it from competitors. The company's progress in preclinical studies and regulatory submissions positions it to potentially capture a share of the growing market for minimally invasive surgical technologies.

Comparison to Industry Standards

• Microbot's focus on a fully disposable robotic system is a unique approach compared to companies like Intuitive Surgical (ISRG) which uses reusable robotic systems.
• The company's preclinical results, with a 95-100% success rate in reaching vascular targets, are promising and compare favorably to other early-stage medical device companies.
• The company's timeline for FDA 510(k) clearance and CE Mark approval is consistent with the typical regulatory pathway for medical devices.
• The company's financial position, with a net loss and reliance on external funding, is typical for a pre-revenue medical device company.

Legal Proceedings

• The company settled a lawsuit for $2.154 million, consisting of a $1.1 million cash payment and 1,005,965 shares of common stock.
• The company is involved in ongoing litigation with Joseph Mona regarding short swing profits.

Stakeholder Impact

• Shareholders face the risk of dilution from future capital raises.
• Employees are subject to the uncertainty of the company's financial stability.
• Customers (potential future users of the LIBERTY system) are impacted by the company's progress in development and regulatory approvals.
• Suppliers and vendors are impacted by the company's financial health and ability to pay for goods and services.
• Creditors are exposed to the risk of the company's potential inability to repay debts.

Next Steps

• The company will continue its interaction with the FDA regarding its IDE submission process.
• The company will commence audits for ISO 13485 certification to support future CE Mark approval.
• The company will continue to seek additional funding through public and private issuances of debt and/or equity securities.
• The company expects to transfer the Technology back to CardioSert in the second fiscal quarter of 2024.

Key Dates

Keywords

robotic surgery, medical device, endovascular, LIBERTY system, FDA, CE Mark, preclinical study, IDE application, financial results, capital raise